GTBP
GT Biopharma, Inc.
There isn't enough reported data to score GTBP yet.
GTBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Under pressure |
GTBP's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
GTBP PE Valuation
GTBP has no meaningful PE right now: it lost money over the past year.
GTBP Forward outlook
There aren't enough analyst estimates for GTBP to show an outlook.
GTBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$295.25 | -$110.75 |
| Q2 2025 | -$359.50 | -$168.25 |
| Q1 2025 | -$140.75 | +$33.75 |
| Q4 2024 | -$173.50 | -$32.50 |
| Q3 2024 | -$184.50 | +$36.92 |
| Q2 2024 | -$191.25 | +$150.17 |
| Q1 2024 | -$174.50 | +$204.42 |
| Q4 2023 | -$141.00 | +$357.92 |
GTBP is still losing money, but far less than before: $295.25 per share over the past year, against $8,542.50 at its worst in late 2019.
GTBP Quarterly Revenue
GTBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.3M | -$1.2M |
| Q1 2026 | -$2.5M | -$266K |
| Q4 2025 | -$4M | -$1.6M |
| Q3 2025 | -$3.7M | -$940K |
| Q2 2025 | -$3M | +$522K |
| Q1 2025 | -$2.2M | +$2M |
| Q4 2024 | -$2.5M | -$421K |
| Q3 2024 | -$2.7M | -$773K |
GTBP has burned cash in almost every quarter: −$14M over the past year, against −$10M the year before.
GTBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +342K shares |
| 1 year | +1555% | +1.5M shares |
| 3 years | +2880% | +1.5M shares |
| 5 years | +7071% | +1.5M shares |
| Available history | +33569% | +1.5M shares |
GTBP has 2M diluted shares, up 1555% from a year ago.
GTBP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | 3.8x | Elevated |
GTBP's net debt is about 3.8 years of its operating earnings (EBITDA).
GTBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 3.4 | Oversold |
GTBP's weekly RSI is 33 (neutral) and its Stochastic is 3 (oversold).
GTBP PE vs Healthcare Sector
GTBP has no meaningful PE right now: it lost money over the past year.
GTBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.72 | 33% below |
| 20 week MA | $7.22 | 47% below |
| 50 week MA | $10.7 | 64% below |
| 100 week MA | $29.2 | 87% below |
| 200 week MA | $108.4 | 96% below |
GTBP is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
GTBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,236.8 | $7,356.8 | +495% |
| 2021 | $7,356.8 | $2,790.0 | -62% |
| 2022 | $2,790.0 | $817.5 | -71% |
| 2023 | $817.5 | $191.3 | -77% |
| 2024 | $191.3 | $75.5 | -61% |
| 2025 | $75.5 | $20.8 | -72% |
| 2026 YTD | $20.8 | $3.84 | -82% |
GTBP has finished five years in a row lower, and it's down 82% so far in 2026.